Impact of multiple primary cancers on overall survival of patients with hepatocellular carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084943" target="_blank" >RIV/00023001:_____/24:00084943 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/25:00563625 RIV/00216208:11110/24:10482059 RIV/61383082:_____/24:00001429
Result on the web
<a href="https://www.elis.sk/download_file.php?product_id=8369&session_id=dcsmjmbn7fpvuktipnon7voqd2" target="_blank" >https://www.elis.sk/download_file.php?product_id=8369&session_id=dcsmjmbn7fpvuktipnon7voqd2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2024_231217N649" target="_blank" >10.4149/neo_2024_231217N649</a>
Alternative languages
Result language
angličtina
Original language name
Impact of multiple primary cancers on overall survival of patients with hepatocellular carcinoma
Original language description
The increasing occurrence of multiple primary cancers (MPC) is a long-term trend, but the prevalence of MPC in patients with hepatocellular carcinoma (HCC) and its impact on overall survival (OS) remains unknown. We retrospectively analyzed 497 patients with HCC treated at two tertiary centers. The cohort was divided into two subgroups - liver transplant (LT, 324 patients) and non-liver transplant (non-LT, 173 patients). We analyzed MPC occurrence, its impact on survival, and identified variables predicting unfavorable outcomes. The MPC were detected in 88 patients (18%). The most common MPC were prostate (17%), skin (15.9%), kidney (12.5%), and lung (10.2%). The median OS of the whole cohort and the LT and non-LT subgroups were 70, 116, and 17 months, respectively (p<0.0001). The median OS in patients with HCC only and HCC with another cancer was 77 (95% CI, 67-96) and 50 months (95% CI, 37-62), respectively (p=0.25). The OS of LT patients was significantly better than that of those in whom LT had been contraindicated owing to concomitant MPC (116 vs. 35 months, p<0.0009). Autoimmune etiology, non-alcoholic steatohepatitis (NASH), HCC as the first diagnosed malignancy, and male sex were identified as factors significantly influencing the patients' outcomes (HR 0.43, 3.2326, 0.70, and 1.43, respectively). The MPC frequency was 18%. The impact of MPC on OS was not significant, except for individuals contraindicated for LT because of MPC. A better prognosis is associated with the autoimmune etiology of cirrhosis, and when HCC is diagnosed as the first malignancy. Male sex and NASH worsened the outcomes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
<a href="/en/project/NV19-08-00525" target="_blank" >NV19-08-00525: Early diagnostics of hepatocellular carcinoma in patients with liver cirrhosis by novel molecular spectrometric biomarkers in blood plasma</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neoplasma
ISSN
0028-2685
e-ISSN
1338-4317
Volume of the periodical
71
Issue of the periodical within the volume
3
Country of publishing house
SK - SLOVAKIA
Number of pages
8
Pages from-to
289-296
UT code for WoS article
001266136900008
EID of the result in the Scopus database
2-s2.0-85197730777